Pomalid (Pomalidomide) 4 mg Capsules
Pomalid 4 mg is a third-generation immunomodulatory drug (IMiD). Active ingredient: Pomalidomide (4 mg).
Manufacturer: Natco Pharma (India). Generic equivalent of Pomalyst / Imnovid.
The "Rescue" Therapy:
Pomalidomide is much more potent than its predecessors (Thalidomide and Lenalidomide). It is specifically engineered to work in patients whose Multiple Myeloma has become resistant (refractory) to other treatments.
β Key Benefit: Offers a vital treatment option for patients who have failed Lenalidomide and Bortezomib therapies.
Indicated for the treatment of adult patients with Relapsed and Refractory Multiple Myeloma (RRMM) who:
- Have received at least two prior treatment regimens, including lenalidomide and bortezomib.
- Have demonstrated disease progression on the last therapy.
Must be administered in combination with low-dose Dexamethasone.
Standard Dose: 4 mg capsule.
Treatment Cycle (28 Days):
- π Days 1 to 21: Take 4 mg orally once daily.
- π Days 22 to 28: Rest period (no medication).
β οΈ Handling Instructions:
- π Swallow whole with water. DO NOT BREAK, CHEW, or OPEN capsules. The powder is toxic and teratogenic.
- Take at the same time each day, with or without food.
π« BLACK BOX WARNING: PREGNANCY (Category X).
Pomalidomide causes severe life-threatening birth defects. Females of reproductive potential must use two effective forms of contraception starting 4 weeks before therapy.
Other Contraindications:
- Breastfeeding.
- Severe hypersensitivity to pomalidomide.
Serious adverse reactions include:
- Hematologic Toxicity: Severe Neutropenia (low white blood cells) is very common. Weekly blood counts required for the first 8 weeks.
- Venous Thromboembolism: High risk of DVT/PE. Anticoagulant prophylaxis (e.g., Aspirin) is mandatory.
- Infections: Increased risk of pneumonia.
- Fatigue and weakness.
What Customers Say
No reviews yet
Your review can be the first!